”Initial high-efficacy disease-modifying therapy in multiple sclerosis: a nationwide cohort study”:
-We found a lower probability of 6-month confirmed EDSS score worsening and lower probability of a first relapse in patients starting a heDMT as first therapy, compared to a matched sample starting meDMT.
-This study provides Class III evidence that for patients with MS, starting heDMT lowers the risk of EDSS worsening and relapses compared to starting meDMT.
-*”Class III evidence”:
Multiple Sclerosis Research Repository 
Leave a comment